Chadi resumes his WCLC review with Dr. Eric Singhi of The University of Texas MD Anderson Cancer Center, exploring the most significant updates in mutation-driven lung cancer presented at this year’s meeting. The discussion dives into advances in sequencing and molecular profiling to identify actionable genomic alterations (AGAs) and how these findings are transforming both early- and late-stage treatment strategies. Dr. Singhi highlights key data from the ADAURA, TARGET, and NAUTIKA1 studies...
All content for Healthcare Unfiltered is the property of Chadi Nabhan and is served directly from their servers
with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.
Chadi resumes his WCLC review with Dr. Eric Singhi of The University of Texas MD Anderson Cancer Center, exploring the most significant updates in mutation-driven lung cancer presented at this year’s meeting. The discussion dives into advances in sequencing and molecular profiling to identify actionable genomic alterations (AGAs) and how these findings are transforming both early- and late-stage treatment strategies. Dr. Singhi highlights key data from the ADAURA, TARGET, and NAUTIKA1 studies...
In this follow-up episode, Dr. Ed Livingston—renowned surgeon, educator, researcher, and former deputy editor at JAMA—returns to discuss the latest developments in his ongoing legal battle. He reflects on what has transpired in the three months since his last appearance, offering insights into the discovery process and the legal details shaping the case as it heads toward a July 2026 trial date.Check out Chadi’s website for all Healthcare Unfiltered episodes and other content. www.chadinabhan...
Healthcare Unfiltered
Chadi resumes his WCLC review with Dr. Eric Singhi of The University of Texas MD Anderson Cancer Center, exploring the most significant updates in mutation-driven lung cancer presented at this year’s meeting. The discussion dives into advances in sequencing and molecular profiling to identify actionable genomic alterations (AGAs) and how these findings are transforming both early- and late-stage treatment strategies. Dr. Singhi highlights key data from the ADAURA, TARGET, and NAUTIKA1 studies...
